{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T06:47:18Z","timestamp":1750661238858,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shijiazhuang No.4 Pharmaceutical Co., Ltd.,"},{"name":"Public Welfare Application Research Project of Huzhou Technology Plan","award":["2021GZ71"],"award-info":[{"award-number":["2021GZ71"]}]},{"name":"Youth Talent Program of Huzhou Central Hospital","award":["2020YC12"],"award-info":[{"award-number":["2020YC12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40268-024-00464-8","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T03:50:06Z","timestamp":1717041006000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single-Dose, Three-Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"chictr2300071630","registry":"10.18810\/chictr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-0600","authenticated-orcid":false,"given":"Yingrong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengli","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyue","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-5251","authenticated-orcid":false,"given":"Shuixin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"issue":"10","key":"464_CR1","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1177\/106002809202601014","volume":"26","author":"CH Ballow","year":"1992","unstructured":"Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother. 1992;26(10):1253\u201361.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"464_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0149-2918(96)80179-2","volume":"18","author":"GW Amsden","year":"1996","unstructured":"Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996;18(1):56\u201372 (discussion 55).","journal-title":"Clin Ther"},{"issue":"2","key":"464_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2163","volume":"31","author":"ME Oliver","year":"2021","unstructured":"Oliver ME, Hinks TSC. Azithromycin in viral infections. Rev Med Virol. 2021;31(2): e2163.","journal-title":"Rev Med Virol"},{"issue":"5","key":"464_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0924-8579(01)00430-7","volume":"18","author":"WL Hand","year":"2001","unstructured":"Hand WL, Hand DL. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents. 2001;18(5):419\u201325.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"464_CR5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1128\/AAC.02011-12","volume":"57","author":"P Matzneller","year":"2013","unstructured":"Matzneller P, Krasniqi S, Kinzig M, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother. 2013;57(4):1736\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"464_CR6","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1128\/AAC.40.11.2577","volume":"40","author":"DR Luke","year":"1996","unstructured":"Luke DR, Foulds G, Cohen SF, et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother. 1996;40(11):2577\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"464_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2165\/00003088-199325050-00003","volume":"25","author":"NJ Lalak","year":"1993","unstructured":"Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993;25(5):370\u20134.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"464_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/jac\/dky548","volume":"74","author":"FYS Kong","year":"2019","unstructured":"Kong FYS, Horner P, Unemo M, et al. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother. 2019;74(5):1157\u201366.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"464_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2165\/00003495-199244050-00007","volume":"44","author":"DH Peters","year":"1992","unstructured":"Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992;44(5):750\u201399.","journal-title":"Drugs"},{"issue":"10","key":"464_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/cpdd.1132","volume":"11","author":"B Ge","year":"2022","unstructured":"Ge B, Li C, Wei H, et al. A Reference-scaled average bioequivalence study of azithromycin tablets manufactured in china and the United States: an open-label, randomized, single-dose, 3-way crossover study in healthy chinese subjects under fasted and fed conditions. Clin Pharmacol Drug Dev. 2022;11(10):1147\u201356.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"9","key":"464_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/cpdd.1098","volume":"11","author":"CW Leong","year":"2022","unstructured":"Leong CW, Yee KM, Nalaiya J, et al. Pharmacokinetics and bioequivalence of 2 azithromycin tablet formulations: a randomized, open-label, 2-stage crossover study in healthy volunteers. Clin Pharmacol Drug Dev. 2022;11(9):1078\u201383.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"6","key":"464_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.5414\/CP201616","volume":"50","author":"MU Ahmed","year":"2012","unstructured":"Ahmed MU, Islam MS, Shohag H, et al. Comparative pharmacokinetic and bioequivalence study of azithromycin 500 mg tablet in healthy Bangladeshi volunteers. Int J Clin Pharmacol Ther. 2012;50(6):452\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"464_CR13","first-page":"471","volume":"59","author":"E Setiawati","year":"2009","unstructured":"Setiawati E, Deniati SH, Yunaidi DA, et al. Bioequivalence study of two azithromycin formulations in healthy subjects. Arzneimittelforschung. 2009;59(9):471\u20135.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"464_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.curtheres.2007.10.005","volume":"68","author":"J Ren","year":"2007","unstructured":"Ren J, Jiang XH, Li K, et al. Bioequivalence of two formulations of a single oral dose of 500-mg azithromycin granules: a randomized, open-label, two-period crossover study in healthy han chinese volunteers. Curr Ther Res Clin Exp. 2007;68(5):369\u201377.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"4","key":"464_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.clinthera.2007.04.010","volume":"29","author":"J Boonleang","year":"2007","unstructured":"Boonleang J, Panrat K, Tantana C, et al. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers. Clin Ther. 2007;29(4):703\u201310.","journal-title":"Clin Ther"},{"issue":"1","key":"464_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/bdd.252","volume":"22","author":"NM Najib","year":"2001","unstructured":"Najib NM, Idkaidek N, Ghanem IE, et al. Bioequivalence assessment of Azomycin (Julphar, UAE) as compared to Zithromax (Pfizer, USA)\u2013two brands of azithromycin\u2013in healthy human volunteers. Biopharm Drug Dispos. 2001;22(1):15\u201321.","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"464_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cpdd.1226","volume":"12","author":"F Wu","year":"2023","unstructured":"Wu F, Zhao X, Guo S, et al. A bioequivalence study with pharmacokinetic endpoints for azithromycin eye drops. Clin Pharmacol Drug Dev. 2023;12(7):761\u20136.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"2","key":"464_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10928-019-09623-w","volume":"46","author":"L Endrenyi","year":"2019","unstructured":"Endrenyi L, Tothfalusi L. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization. J Pharmacokinet Pharmacodyn. 2019;46(2):117\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00464-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00464-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00464-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T10:27:19Z","timestamp":1723199239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00464-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00464-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"21 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Shijiazhuang No.4 Pharmaceutical Co., Ltd., Hebei, China, Public Welfare Application Research Project of Huzhou Technology Plan (Grant number 2021GZ71) and Youth Talent Program of Huzhou Central Hospital (Grant number 2020YC12).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JW is an employee of Shijiazhuang No.4 Pharmaceutical Co., Ltd. YRC, LBY, JM, MLT, MX, QYJ, XY and SXY report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study was approved by the Ethics Committee at Huzhou Central Hospital on December 09, 2020 (Approval No. 202112015-01). The written informed consents was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All study participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All researchers, participants, institutions, and sponsors consented to the submission of this report to the journal.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The study was conceptualized and designed by SXY and JW. YRC analyzed the data and wrote the article. Material preparation and data collection were performed by LBY, JM, MLT, MX, QYJ and XY. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}